- Home
- GATX vs NUVL Comparison
GATX vs NUVL Comparison
Compare GATX & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GATX
- NUVL
- Stock Information
- Founded
- GATX 1898
- NUVL 2017
- Country
- GATX United States
- NUVL United States
- Employees
- GATX N/A
- NUVL N/A
- Industry
- GATX Transportation Services
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- GATX Consumer Discretionary
- NUVL Health Care
- Exchange
- GATX Nasdaq
- NUVL Nasdaq
- Market Cap
- GATX 5.9B
- NUVL 5.5B
- IPO Year
- GATX N/A
- NUVL 2021
- Fundamental
- Price
- GATX $161.92
- NUVL $79.49
- Analyst Decision
- GATX Buy
- NUVL Strong Buy
- Analyst Count
- GATX 2
- NUVL 11
- Target Price
- GATX $162.50
- NUVL $112.36
- AVG Volume (30 Days)
- GATX 125.5K
- NUVL 412.9K
- Earning Date
- GATX 01-23-2025
- NUVL 03-04-2025
- Dividend Yield
- GATX 1.51%
- NUVL N/A
- EPS Growth
- GATX 9.27
- NUVL N/A
- EPS
- GATX 7.78
- NUVL N/A
- Revenue
- GATX $1,585,500,000.00
- NUVL N/A
- Revenue This Year
- GATX $10.19
- NUVL N/A
- Revenue Next Year
- GATX $5.72
- NUVL N/A
- P/E Ratio
- GATX $20.77
- NUVL N/A
- Revenue Growth
- GATX 12.38
- NUVL N/A
- 52 Week Low
- GATX $122.00
- NUVL $61.80
- 52 Week High
- GATX $168.89
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- GATX 47.14
- NUVL 43.83
- Support Level
- GATX $161.43
- NUVL $77.84
- Resistance Level
- GATX $168.89
- NUVL $85.21
- Average True Range (ATR)
- GATX 2.90
- NUVL 3.78
- MACD
- GATX -0.59
- NUVL -0.46
- Stochastic Oscillator
- GATX 6.57
- NUVL 12.08
About GATX GATX Corporation
GATX Corp is a provider of railcar leasing and maintenance services. GATX operates four business segments: rail North America, rail international, and portfolio management. The rail business offers railcar leasing and maintenance, as well as asset-related, financial, and management services. The company owns and leases fleets in North America, Europe, and Asia, which consist of tank and freight railcars. Industries served include refining and petroleum, chemicals and plastics, railroads and other transportation, mining, and food and agriculture.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.